Novo Nordisk A/S Class B

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B carries a market capitalization of 862.87B, placing it among publicly traded companies globally. Its enterprise value stands at 932.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B's next confirmed earnings release is scheduled for February 3, 2027.

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B has 35.10B shares outstanding.

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B trades at a trailing price-to-earnings ratio of 9.74. The price-to-sales ratio is 3.30, and the price-to-book ratio stands at 5.04.

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B trades at an EV/EBITDA multiple of 7.07 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 8.39 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B trades at an EV/FCF ratio of 25.42, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 932.12B versus a market cap of 862.87B, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B maintains a current ratio of 0.84, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 61.74, indicating elevated leverage, while an interest coverage ratio of 77.37 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B posted a return on equity (ROE) of 58.38, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 32.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 20.37, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 36.85, useful for judging operating efficiency across full business cycles. The company generates approximately 3.81M in revenue per employee across its workforce of 68,794.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.30 indicates how many times Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B recorded 24.74B in income tax expense. That works out to an effective tax rate of 21.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 113.66B, leaving 88.92B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on November 6, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B's stock has declined approximately 9.98% over the past 52 weeks. The 50-day moving average sits at 26.44, while the 200-day moving average is 28.31.

Over the twelve months ended September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B generated 262.15B in revenue and converted that into 88.92B in net income, yielding earnings per share of 2.52. EBITDA reached 131.91B, while operating income came in at 111.12B.

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B holds 36.42B in cash and equivalents against 105.66B in total debt, resulting in a net debt position of 70.97B. Total book value stands at 171.13B, with working capital of -30.39B providing operational flexibility.

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B produced 100.04B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -64.71B in capital expenditures, free cash flow totaled 35.33B - equivalent to 1.00 per share.

Over the twelve months ended September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B posted a gross margin of 80.79, reflecting its pricing power and cost economics. The operating margin of 42.39 and net profit margin of 33.92 provide insight into operational efficiency.

Over the twelve months ended September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B paid dividends of 1.16 per share. The dividend payout ratio of 45.85 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.07, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.90, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B shareholders.

Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B's most recent stock split took place on September 20, 2023 with a 1:2 split ratio.

As of September 30, 2026, Novo Nordisk A/S ADR B Unsponsored Brazilian Depositary Receipt Repr 0.125 ADR B has an Altman Z-Score of 3.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.